DANA: Last year, 2017, was a transformational year for Lazarex Cancer Foundation. We celebrated our 10-year anniversary – 10 years from assisting Ian, our 1st patient in 2007. We received a $2 million grant from Amgen to launch our Lazarex IMPACT initiative. As part of our strategic plan, we hired an Executive Director, a big step for Lazarex and for me. Dr. Vera Packard joined our team on October 5th!

I have transitioned from President and Founder of Lazarex Cancer Foundation to Chairman of the Board and Founder. In my new role I will continue to develop our IMPACT (IMproving Patient Access to Cancer Clinical Trials) initiative to create a sustainable solution to the systemic problem that Lazarex is addressing with our program services.

To all of you who support Lazarex, you have my deepest thanks and appreciation for stepping up. A decade later, Lazarex has evolved into something much greater than I ever imagined. We need you more than ever as new patient requests continue to skyrocket. I ask you to continue to support Lazarex because you believe in our mission and the work we are doing that is changing the outcome of cancer care for so many, now and in the future. This is our legacy of love.

VERA: I am honored and humbled by the opportunity to join the Lazarex family. It’s a blessing to bring the lessons and experiences from my two careers, as a breast cancer surgeon in Brazil for 20 years and Executive Director here in the US for the past 9 years, together to help Lazarex continue to grow and deliver its mission to as many clients as possible. The Lazarex mission is transformational, and it’s the main reason I wanted to join the organization. Warren Buffet once said, “Someone is sitting in the shade today because someone planted a tree a long time ago.” I hope to help Lazarex plant many trees, so cancer survivors can enjoy the shade, and live a better life despite having cancer.
We’re getting the word out about Lazarex via community events, social media, news sources, even word of mouth. A stir about our social impact is what we need to change things and to assist more cancer patients in need. Help us get our message “out there” by sharing something about Lazarex today on your favorite media platforms.

86% of our patients* receive reimbursement for 100% of expenses.

*up to 400% of federal poverty guidelines

Connect with us on Instagram, Twitter, Facebook and LinkedIn.

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>

We have relationships with 193 CLINICAL TRIAL SITES:

47 out of 50 NCI-designated Comprehensive Cancer Centers

6 out of the 12 NCI-designated Cancer Centers

140 other Cancer Centers

OUR REIMBURSEMENT PROGRAMS and Percentage of use by our Patients

<table>
<thead>
<tr>
<th>Program</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Give Hope a Ride</td>
<td>18%</td>
</tr>
<tr>
<td>Home Away from Home</td>
<td>21%</td>
</tr>
<tr>
<td>Wings of Love</td>
<td>22%</td>
</tr>
<tr>
<td>Fueling Hope</td>
<td>39%</td>
</tr>
</tbody>
</table>
The Problem  Patient participation is crucial to the successful completion of a trial.  Obstacles to participation – primarily the out of pocket expenses – add to a patient’s financial burden at a time when they can least afford it, creating a barrier. While the Lazarex Care program helps patients access clinical trial treatments today, it does not sustainably remove the cost barrier that keeps patients out of clinical trials.

The Solution  In 2013, Lazarex and #1 ranked Massachusetts General Hospital formed the Lazarex MGH Cancer Care Equity Program (now re-branded as IMPACT) and achieved a 29% increase in overall participation and doubled minority participation in MGH cancer clinical trials in the 3 year study.

IMPACT (IMproving Patient Access to Cancer Clinical Trials) is a Lazarex program that coordinates efforts amongst many stakeholders: academia, medicine, policymakers, industry, public health and community organizations. It will create a new standard to bring sustainable change to the status quo of clinical trial recruitment. IMPACT will increase patient enrollment, retention, minority participation, completion, and translational science – providing sustainable, equitable and timely patient access to cancer discovery.

For a more detailed look at the IMPACT program please visit https://www.lazarex.org/impact

Carolyn: I was stressing. Is this [trial] something I can commit to – monthly travel, copays and medical expenses? Because of Lazarex, I could say YES, I’m willing to do this.

Anthony: Without Lazarex and their donors, I’m not sure if I’d be around to share my story. With your support, I will continue to fight until WE overcome this!

AMGEN  IMPACT Founding Sponsor

Sidney Kimmel Cancer Center  at Jefferson  NCI – designated

Herrick

USCDornsife  Dana and David Dornsife College of Letters, Arts and Sciences
2017 Revenue and Expenses

**Revenue**

- Grants: $3,794,381
- Corporation Contributions: $100,000
- Individual Donations: $1,184,793
- In-kind contributions: $29,752
- Other income: $254,438

**Expenses**

- Program Services: $3,031,127
- Management & General: $112,378
- Fundraising: $184,407

*2,000,000 are restricted funds received in 2017 for our IMPACT Program Services in 2018*

**Revenues**

- $5,363,364

- 71% Grants
- 22% Program Services
- 5% Management & General
- 3% Fundraising
- <1% Other income

- 91% of donations applied directly to program services

We have assisted over 3,000 patients with financial assistance and patient navigation for FDA clinical trial participation.

$14,243,434 has been spent on program services since we served our first patient, Ian, pictured above.

Cancer patients from all 50 states and 18 countries received assistance with clinical trial participation in FDA clinical trials.

Advisory Council
- Dr. Robert Johnson, Chief Medical Officer
- Dave Dornsife
- Kelly Milligan
- Roger Schwab

Audit Committee
- Clay Jackson
- Greg Meyer
- Roger Schwab

Board of Directors
- Dana Dornsife, Chair
- Dr. Frank Crnkovich
- Elizabeth Dale
- Martha Escutia
- Vance Farrow
- Greg Francisco
- Clay Jackson
- Dr. Beverly Moy
- Karen Sessions
- Dr. Marya Shegog
- Dr. Kenny Simansky
- Frank Varenchik, CFO

Development Committee
- Elizabeth Dale, Chair
- Christopher Brittin
- Clay Jackson
- Maribel Montanez
- Karen Sessions

Development Task Force
- Joanne Bradford
- Christopher Brittin
- Al Checcio
- Elizabeth Dale
- Sara Young Jackson
- Sam Jackson

Finance Committee
- Frank Varenchik, Chair
- Burt Bassler
- Eileen Chew
- Clay Jackson
- Kelly Milligan
- Roger Schwab

Staff
- Dana Dornsife, President
- Dr. Vera Packard, Executive Director
- Karen Ambrogi, Communications Manager
- Jade Atkins, Event Coordinator
- Susan Blick, Development Assistant
- Jenny Grau, Financial Manager
- Tami Keeler, Office and Patient Services Manager
- Erin Miller, Outreach Coordinator
- Maribel Montanez, Chief Advancement Officer
- Ryan Noonan, Patient Intake Assistant
- Ronna Spaan, Bookkeeping Patient Assistant
- Karen Weixel, Patient Navigator
- Paige Wycoff, Patient Navigator

Heartwarming **THANKS** to our volunteers who in 2017 gave Lazarex **6030 hours** of their valuable time.

Lazarex
Cancer Foundation
It’s About Living

PO Box 741
Danville, CA 94526-0741
925.820.4517
925.552.7305 fax
www.lazarex.org